Lesson plan

Temanogrel

Temanogrel ( , ; developmental code name APD791) is a serotonin 5-HT 2A receptor antagonist and inverse agonist which is under development for the treatment of myocardial ischemia and Raynaud's disease. It was also being developed for arterial thrombosis and acute coronary syndromes, but development for the former use was suspended and development for the latter indication was discontinued. The drug is taken orally. Temanogrel is highly selective for the serotonin 5-HT 2A receptor, with more than 2,000-fold selectivity for this receptor over the serotonin 5-HT 2B and 5-HT 2C receptors and lack of activity at a variety of other G protein-coupled receptors (GPCRs). As of September 2022, it is in phase 2 clinical trials for myocardial ischemia and Raynaud's disease.

Back to article

Article summary

Temanogrel ( , ; developmental code name APD791) is a serotonin 5-HT 2A receptor antagonist and inverse agonist which is under development for the treatment of myocardial ischemia and Raynaud's disease. It was also being developed for arterial thrombosis and acute coronary syndromes, but development for the former use was suspended and development for the latter indication was discontinued. The drug is taken orally. Temanogrel is highly selective for the serotonin 5-HT 2A receptor, with more than 2,000-fold selectivity for this receptor over the serotonin 5-HT 2B and 5-HT 2C receptors and lack of activity at a variety of other G protein-coupled receptors (GPCRs). As of September 2022, it is in phase 2 clinical trials for myocardial ischemia and Raynaud's disease.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.